Aeterna Zentaris (NASDAQ:AEZS) is up 8.5% premarket after announcing favorable results for a Phase 3 study related to its AEZS-130 drug for treating adult growth hormone deficiency. The company now plans to consult with the FDA regarding the submission of a new drug application (NDA).